Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron Inc. (NASDAQ: LGVN) has selected Biorasi LLC as its clinical research organization to conduct a Phase 2 clinical trial evaluating its Lomecel-B infusion for Alzheimer’s Disease. This partnership aims to enhance the development of Lomecel-B, a cell-based therapy derived from medicinal signaling cells, targeting chronic aging-related conditions. The trial is expected to commence by the end of this year or early 2022, as per Kevin N. Ramdas, MD, MPH from Longeveron. Biorasi’s extensive experience in neurology studies positions them as a strong collaborator for this project.
Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company, has activated two new clinical sites for the ELPIS II Trial, which assesses Lomecel-B injections for infants with Hypoplastic Left Heart Syndrome (HLHS). The trial, now in Phase 2, aims to enroll 38 infants and is funded by the NIH's NHLBI. The newly added sites are Advocate Children’s Hospital and Primary Children’s Hospital in Utah. CEO Geoff Green emphasized the importance of these additions for timely execution and increased participation options for families.
Longeveron (NASDAQ: LGVN) announced that CEO Geoff Green will present at the Dawson James Small Cap Growth Conference on October 21, 2021, at 11:25 a.m. ET, in Jupiter, Florida. The presentation will focus on the company's progress in clinical research programs for Alzheimer’s disease, Aging Frailty, and Hypoplastic Left Heart Syndrome. Attendees can access a live webcast via the company's Investors & Media section. Longeveron is developing cell-based therapies aimed at chronic and aging-related conditions, with ongoing Phase 1 and 2 clinical trials for various indications.
Longeveron Inc. (NASDAQ: LGVN) announced positive preliminary results from its Phase 2b trial of Lomecel-B in Aging Frailty subjects. At 270 days, Lomecel-B significantly reduced the biomarker Tie-2 compared to placebo, showcasing a dose-dependent response. In particular, the high-dose group (200 million cells) exhibited a decrease of -936.85 pg/mL (p=0.0095) in sTIE-2 levels, indicating improved vascular health. Additionally, frail subjects showed improved exercise tolerance, walking an average of 47.9 meters further after 270 days. Results were presented at the International Conference for Frailty & Sarcopenia Research.
Longeveron Inc. (NASDAQ: LGVN) announced its Lomecel-B research will be highlighted in presentations and a roundtable at the 11th Annual International Conference on Frailty & Sarcopenia Research (ICFSR) from September 29 to October 2, 2021. The roundtable will cover Phase 2b study results of Lomecel-B in aging frailty. Oral presentations will focus on the safety and efficacy of Lomecel-B in aging frailty patients and the evaluation of its intravenous delivery on antibody responses. This event aims to accelerate clinical trials for aging-related treatments.
Longeveron Inc. (NASDAQ: LGVN) announced that Dr. Jorge Ruiz will present the results of the Phase 2b trial of Lomecel-B, focusing on its efficacy in treating aging frailty, at the ICFSR conference from September 29 to October 1, 2021. The study funded by the National Institute on Aging demonstrated a significant, dose-dependent improvement in walking distance among frail subjects after infusion, particularly in those receiving 200 million cells. Results indicated a 50-meter increase in walking distance at 180 days, suggesting the potential of Lomecel-B as a treatment for aging-related conditions.
Longeveron Inc. (NASDAQ: LGVN) has partnered with Kinesiometrics Inc. to leverage their digital data-driven technology for enhanced measurement of functional capacity and quality of life in clinical studies involving Lomecel-B.
Following a recent Phase 2b study that showed significant improvements in walking distance for older frail subjects post-infusion, this collaboration aims to provide real-time data collection through a mobile application. This innovation is expected to improve patient monitoring and potentially aid regulatory processes by offering detailed insights into treatment outcomes.
Longeveron Inc. (NASDAQ: LGVN) announced promising results from its Phase I clinical trial of Lomecel-B for treating Hypoplastic Left Heart Syndrome (HLHS). The study reported no major adverse cardiac events or treatment-related infections within the first month post-treatment. Impressively, 100% of the infants injected with Lomecel-B remained alive and heart-transplant free after one year, a significant improvement over the historical rate of 78%. The transition to a Phase 2 trial further aims to evaluate Lomecel-B's safety and effectiveness in a controlled setting.
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the H.C. Wainwright 23rd Annual Global Investor Conference, with a virtual presentation available for on-demand viewing starting September 13, 2021. Longeveron specializes in cellular therapies for chronic, aging-related conditions. Their lead product, Lomecel-B, aims to address serious disorders like Aging Frailty and Alzheimer’s disease. Following the presentation, an archived webcast will be accessible for up to 90 days on their website.
Longeveron Inc. (NASDAQ: LGVN) reported favorable outcomes from its Phase 2b trial of Lomecel-B, a therapy aimed at addressing Aging Frailty. At Day 180, patients receiving higher doses (50M, 100M, 200M) exhibited a statistically significant increase in six-minute walk test distances compared to placebo. While pairwise comparisons to placebo did not achieve significance, exploratory results at Day 270 indicated notable improvements. Longeveron plans to advance its research and discuss findings with regulatory authorities, as no serious adverse events were reported, maintaining a positive safety profile for Lomecel-B.